JAMA Oncology Author Interviews – Détails, épisodes et analyse
Détails du podcast
Informations techniques et générales issues du flux RSS du podcast.

JAMA Oncology Author Interviews
JAMA Network
Fréquence : 1 épisode/30j. Total Éps: 122

Classements récents
Dernières positions dans les classements Apple Podcasts et Spotify.
Apple Podcasts
🇫🇷 France - medicine
09/03/2025#85🇫🇷 France - medicine
08/03/2025#62
Spotify
Aucun classement récent disponible
Liens partagés entre épisodes et podcasts
Liens présents dans les descriptions d'épisodes et autres podcasts les utilisant également.
See allQualité et score du flux RSS
Évaluation technique de la qualité et de la structure du flux RSS.
See allScore global : 43%
Historique des publications
Répartition mensuelle des publications d'épisodes au fil des années.
Academic-Community Partnership and Deaths in Promyelocytic Leukemia
jeudi 27 février 2025 • Durée 18:46
Interview with Anand P. Jillella, MD, author of Academic-Community Partnership and Deaths in Promyelocytic Leukemia: The Nonrandomized ECOG-ACRIN EA9131 Trial. Hosted by Vivek Subbiah, MD.
Related Content:
Intracranial Outcomes in Melanoma Brain Metastases After Anti–PD-1 Therapy
jeudi 30 janvier 2025 • Durée 11:55
Interview with Michael A. Postow, MD, author of Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy. Hosted by Vivek Subbiah, MD.
Related Content:
Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time
jeudi 21 mars 2024 • Durée 25:53
Interview with Tobias Janowitz, MD, PhD, and Karen Winkfield, MD, PhD, authors of Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time. Hosted by Vivek Subbiah, MD.
Related Content:
Adjuvant Endocrine Therapy and Risk of Contralateral Breast Cancer
jeudi 6 octobre 2016 • Durée 03:01
Interview with Gretchen L. Gierach, PhD, author of Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting
Prognostic Factors for Local Control in Breast Cancer With Boost vs No Boost
jeudi 8 septembre 2016 • Durée 07:47
Interview with Conny Vrieling, MD PhD, author of Prognostic Factors For Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial
ESR1 Mutations in Metastatic Breast Cancer
jeudi 11 août 2016 • Durée 06:19
Interview with Sarat Chandarlapaty, MD, PhD, author of Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial
Outcomes for Biomarker-Based Treatment Strategies in Refractory Malignant Neoplasms
lundi 6 juin 2016 • Durée 06:25
Interview with Razelle Kurzrock, MD, author of Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis
Physiologic Frailty in Hematopoietic Cell Transplantation Patients
jeudi 2 juin 2016 • Durée 05:23
Interview with Smita Bhatia, MD, MPH, author of Physiologic Frailty in Nonelderly Hematopoietic Cell Transplantation Patients: Results From the Bone Marrow Transplant Survivor Study
Lifestyle Associations With US Cancer Incidence and Mortality
jeudi 19 mai 2016 • Durée 07:14
Interview with Mingyang Song, MD, ScD, author of Preventable Incidence and Mortality of Carcinoma Associated With Lifestyle Factors Among Whites in the United States
Neratinib vs Trastuzumab for Untreated Metastatic ERBB2-Positive Breast Cancer
jeudi 14 avril 2016 • Durée 17:31
Interview with Ahmad Awada, MD, PhD, author of Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial, and Mark D. Pegram, MD, author of Neratinib in ERBB2-Positive Brain Metastases